Patients With Cancer and CHD Diagnosed Between 1999 and 2013 With Updated Smoking Status Who Were Advised to Quit and Prescribed Smoking Cessation Medication Within the First Year After Diagnosis
| Smokers and <3-y Ex-Smokers (All Cancer, n=12,393; CHD, n=12,393)a | Current Smokers Only (All Cancer, n=10,794; CHD, n=10,794)b | ≥1-y Survivors Only (All Cancer, n=4,228; CHD, n=4,228)c | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Outcome | Cancer No. (%) | CHD Control No. (%) | OR (95% CI) | Cancer No. (%) | CHD Control No. (%) | OR (95% CI) | Cancer No. (%) | CHD Control No. (%) | OR (95% CI) |
| Updated smoking status | |||||||||
| All cancers | 4,541 (37) | 9,627 (78) | 0.18 (0.17–0.19) | 3,962 (37) | 8,437 (78) | 0.18 (0.17–0.19) | 2,605 (62) | 3,611 (86) | 0.26 (0.23–0.29) |
| Lung cancer | 2,873 (31) | 7,224 (77) | 0.14 (0.13–0.15) | 2,454 (31) | 6,253 (78) | 0.13 (0.12–0.14) | 1,404 (60) | 1,982 (84) | 0.25 (0.22–0.29) |
| Bladder cancer | 1,172 (57) | 1,620 (79) | 0.38 (0.33–0.44) | 1,055 (57) | 1,466 (79) | 0.38 (0.33–0.44) | 851 (65) | 1,138 (87) | 0.28 (0.22–0.34) |
| Upper aerodigestive tract cancer | 496 (50) | 783 (79) | 0.27 (0.22–0.33) | 453 (50) | 718 (79) | 0.27 (0.22–0.33) | 350 (61) | 502 (87) | 0.23 (0.17–0.30) |
| Advice to quit | |||||||||
| All cancers | 2,794 (23) | 5,601 (45) | 0.38 (0.36–0.40) | 2,636 (24) | 5,245 (48) | 0.36 (0.34–0.38) | 1,630 (39) | 2,156 (51) | 0.60 (0.55–0.66) |
| Lung cancer | 1,672 (18) | 4,196 (45) | 0.28 (0.26–0.30) | 1,564 (19) | 3,907 (49) | 0.26 (0.24–0.28) | 810 (34) | 1,182 (50) | 0.49 (0.43–0.56) |
| Bladder cancer | 809 (39) | 925 (45) | 0.87 (0.76–0.99) | 774 (42) | 880 (48) | 0.86 (0.75–0.98) | 594 (46) | 669 (51) | 0.84 (0.70–0.99) |
| Upper aerodigestive tract cancer | 313 (31) | 480 (48) | 0.50 (0.41–0.60) | 298 (33) | 458 (50) | 0.50 (0.41–0.60) | 226 (39) | 305 (53) | 0.58 (0.46–0.74) |
| Prescriptions | |||||||||
| All cancers | 1,504 (12) | 2,560 (21) | 0.67 (0.63–0.73) | 1,439 (13) | 2,426 (22) | 0.67 (0.62–0.72) | 882 (21) | 967 (23) | 1.05 (0.94–1.17) |
| Lung cancer | 989 (11) | 1,950 (21) | 0.58 (0.53–0.63) | 940 (12) | 1,835 (23) | 0.57 (0.52–0.63) | 498 (21) | 547 (23) | 1.06 (0.91–1.23) |
| Bladder cancer | 291 (14) | 386 (19) | 0.96 (0.81–1.16) | 279 (15) | 373 (20) | 0.97 (0.81–1.16) | 226 (17) | 280 (22) | 1.02 (0.83–1.25) |
| Upper aerodigestive tract cancer | 224 (22) | 224 (22) | 1.00 (0.80–1.24) | 220 (24) | 218 (24) | 1.03 (0.83–1.29) | 158 (27) | 140 (24) | 1.18 (0.89–1.55) |
CHD = coronary heart disease; UAT = upper aeordigestive tract.
↵a Cancer subgroup patients and 1-to-1 matched CHD control patients: lung, n = 9,347; bladder, n = 2,050; UAT, n = 996.
↵b Cancer subgroup patients and 1-to-1 matched CHD control patients: lung, n = 8,037; bladder, n = 1,848; UAT, n = 909.
↵c Cancer subgroup patients and 1-to-1 matched CHD control patients: lung, n = 2,350; bladder, n =1,302; UAT, n = 576.